Online Presentation: Breakthrough Treatment Of Pain by Nutra Pharma (OTC:NPHC) Print E-mail
By Michael Vlaicu   
Wednesday, 02 September 2009 08:54

StocksHaven Investments has confirmed they are set to profile Nutra Pharma Corp. (NPHC.ob) in the coming days, and states that they have also touched base with with Investor Relations in regards to scheduling a tentative conference call with the Chairman and CEO, Rik J Deitsch. Nutra Pharma has recently made waves within the biotech space with their recent “Best New Product” award winning drug, Cobroxin.

The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. The company is also developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS).

Over 50 million Americans suffer from ongoing chronic pain, but that’s all about to change. In August, a biotechnology company, Nutra Pharma, shook the pain world when it announced the launch of Cobroxin, a safe and effective over-the-counter treatment for chronic pain. Unlike many popular pain medicines, Cobroxin does not rely on opiates or acetaminophen for its pain relieving effects. Instead, it uses small peptides from the venom of one of the deadliest animals on Earth – the cobra. Join Nutra Pharma’s Chairman and CEO, Rik J Deitsch, as he explores the science behind this revolutionary new pain killer and how Cobroxin will change the way chronic pain is treated in America and abroad.

The company also seems to have arrived on the scene for stage 2 pain relief at an ideal time, seeing as how the FDA has recently issued warnings on products that contain Ibuprophen. With the prescription pain relief market totaling nearly $14 billion, expected Nutra Pharma to enter FDA clinical trials in the near future with almost certain success, seeing as how it has proven to be more powerful than morphine with less side effects and no addictive properties.

Date: Thursday, September 10, 2009
Time: 9:00 PM – 10:30 PM ET

To sign up and join the webinar, visit https://www2.gotomeeting.com/register/136863971


About Nutra Pharma Corp.

Nutra Pharma Corp. is a development-stage biopharmaceutical company engaged in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. The Company’s wholly owned subsidiary, ReceptoPharm, Inc. (Recepto Pharm) is a development stage biopharmaceutical company, which is engaged in developing technologies to treat the neurological diseases: multiple sclerosis; adrenomyeloneuropathy; amyotrophic lateral sclerosis; myasthenia gravis; and to treat the viral diseases, human immunodeficiency virus (HIV) and hepatitis-C. The Company’s other wholly owned subsidiary Designer Diagnostics, Inc. (Designer Diagnostics) is engaged in marketing diagnostic test kits that are used for the rapid identification of infectious human diseases, such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI).

—–

Disclosure: Position in NPHC

—–

By reading StocksHaven Investments you agree to the disclaimer, and thereby will not hold Michael Vlaicu accountable for any transactions or decisions you make. It is up to you to do your own due diligence.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter